Vall d'Hebron Institute of Oncology (VHIO)
Susana Munoz has a wealth of experience in the field of oncology clinical trials development. From their time as the Breast Clinical Trials Office Head at Hospital Universitari de la Vall d'Hebron to their current role as the Clinical research support unit Head at Vall d´Hebron Institute of Oncology (VHIO), Susana has demonstrated expertise and leadership in the management of clinical research projects. Additionally, their role as Co-Directora of the Curso Ensayos Clínicos en Oncología para coordinadores/Monitores showcases their dedication to advancing knowledge and skills in the field of oncology clinical trials.
Vall d'Hebron Institute of Oncology (VHIO)
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO) has established itself as a cancer research center of proven excellence internationally. It is thanks to Josep's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease. Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron University Hospital physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread and more effectively treating even the most undruggable tumour types. VHIO's translation toward precision oncology.